<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966160</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-1999-LRE</org_study_id>
    <nct_id>NCT00966160</nct_id>
  </id_info>
  <brief_title>CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes</brief_title>
  <official_title>Phase 3, Single Center, Controlled, Investigator-blinded, Randomized Matched Pair Design Study of CD4 Cell Recovery in HIV-1 Patients With Sustained Virologic Response Comparing Protease Inhibitor and Non-nucleoside Reverse Transcriptase Inhibitor Based Treatment Regimes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <brief_summary>
    <textblock>
      Therapy guidelines recommend the use of either the non-nucleoside reverse transcriptase
      inhibitor (NNRTI) efavirenz or a ritonavir-boostered protease inhibitor (PI) plus 2
      nucleoside reverse transcriptase inhibitors (NRTI) as first-line treatment regimes of HIV-1
      infection. Recent clinical studies suggest potential advantages of NNRTI- over PI-based
      regimes in therapy initiation due to lower rates of virologic failure and less metabolic
      side-effects. In contrast, PI regimes were claimed to cause greater increases in CD4 cell
      count than NNRTI regimes, which has been attributed to intrinsic antiapoptotic effects of the
      PI. However, it is still unclear whether the immunological response to a PI-containing regime
      is greater than to an NNRTI-containing regime, whether there is a difference in the extent of
      reduction of apoptosis between PI and NNRTI regimes and whether a difference in apoptosis is
      associated with a difference in CD4 cell recovery.

      We conducted a controlled, long-term, random matched pair design study in HIV-1 infected
      individuals under sustained virologic suppression to evaluate in head-to-head comparison the
      clinical effects of a constant PI-based or NNRTI-based regime on CD4 cell recovery and the
      underlying molecular, biochemical and functional mechanisms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in changes of CD4 cell count between PI and NNRTI groups</measure>
    <time_frame>420 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of CD4 cell counts</measure>
    <time_frame>420 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular, biochemical and functional markers of CD4 cell apoptosis</measure>
    <time_frame>420 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>PI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNRTI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir plus Lamivudine/Zidovudine</intervention_name>
    <description>400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks</description>
    <arm_group_label>PI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz plus Lamivudine/Zidovudine</intervention_name>
    <description>600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks</description>
    <arm_group_label>NNRTI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recent, non-acute HIV-1 infection

          -  Caucasians

          -  BMI between 17.5 and 30 kg/m2

          -  CD4 count &lt;200 cells/Âµl

          -  Plasma viral load &gt;100,000 HIV-1 RNA copies/ml

        Exclusion Criteria:

          -  Actual or previous antiretroviral therapy

          -  Acute illness

          -  Coinfection with HBV or HCV

          -  Opportunistic infection (Pneumocystis jiroveci pneumonia, Toxoplasma gondii
             encephalitis, Mycobacterium ssp. infection, syphilis, cryptosporidiosis,
             cryptococcosis, aspergillosis, cytomegalovirus infection or progressive multifocal
             leukoencephalopathy)

          -  Hepatic or renal disorder

          -  Severe cardiovascular disease

          -  Hematologic disorder

          -  Autoimmune disorder

          -  Diabetes mellitus or other severe endocrine disorder

          -  Malignancy

          -  Neurocognitive disorder

          -  Psychiatric disorder

          -  Drug or alcohol addiction

          -  Chronic drug use (except of blood pressure-lowering or lipid-lowering drugs or
             proton-pump inhibitors)

          -  Any acute medication within 7 days or vaccination within 30 days prior to entry

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Taubert, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Pharmacology, University of Cologne, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Clinic I and Department of Pharmacology, University of Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609.</citation>
    <PMID>18480202</PMID>
  </reference>
  <reference>
    <citation>Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999 Dec 16;341(25):1865-73.</citation>
    <PMID>10601505</PMID>
  </reference>
  <reference>
    <citation>Badley AD, Pilon AA, Landay A, Lynch DH. Mechanisms of HIV-associated lymphocyte apoptosis. Blood. 2000 Nov 1;96(9):2951-64. Review.</citation>
    <PMID>11049971</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2009</study_first_submitted>
  <study_first_submitted_qc>August 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2009</study_first_posted>
  <last_update_submitted>September 28, 2009</last_update_submitted>
  <last_update_submitted_qc>September 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dirk Taubert</name_title>
    <organization>University of Cologne</organization>
  </responsible_party>
  <keyword>treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

